Salivary Gland Protection by Amifostine in High-dose Radioiodine Therapy of Differentiated Thyroid Cancer

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 1999 Mar 5

PMID 10065139

Citations 12

Authors

K H Bohuslavizki

S Klutmann

C Bleckmann

W Brenner

S Lassmann

J Mester

E Henze

M Clausen

Affiliations

Soon will be listed here.

Abstract

Background: Salivary gland impairment following high-dose radioiodine treatment is a well-recognized side effect, in general caused by free radicals. Therefore, it seemed promising to evaluate the radioprotective effect of the radical scavenger amifostine in patients receiving high-dose radioiodine therapy.

Patients And Method: Quantitative salivary gland scintigraphy using 100 to 120 MBq Tc-99m-pertechnetate was performed in 17 patients with differentiated thyroid cancer prior to and 3 months after radioiodine treatment with 6 GBq I-131. Eight patients were treated with 500 mg/m2 amifostine prior to high-dose radioiodine treatment and compared retrospectively with 9 control patients. Xerostomia was graded according to WHO criteria.

Results: In 9 control patients high-dose radioiodine treatment significantly (p < 0.01) reduced Tc-99m-pertechnetate uptake by 35.4 +/- 22.0% and 31.7 +/- 21.1% in parotid and submandibular glands, respectively. Of these 9 patients, 3 exhibited xerostomia Grade I (WHO). In contrast, in 8 amifostine-treated patients, there was no significant (p = 0.878) decrease in parenchymal function following high-dose radioiodine treatment, and xerostomia did not occur in any of them.

Conclusion: Parenchymal damage in salivary glands induced by high-dose radioiodine treatment can be reduced significantly by amifostine. This may help to increase patients' quality of life in differentiated thyroid cancer.

Citing Articles

Radiotheranostics in oncology: current challenges and emerging opportunities.

Bodei L, Herrmann K, Schoder H, Scott A, Lewis J Nat Rev Clin Oncol. 2022; 19(8):534-550.

PMID: 35725926 PMC: 10585450. DOI: 10.1038/s41571-022-00652-y.

Early Quantification of Salivary Gland Function after Radioiodine Therapy.

Singh Tanwar K, Rana N, Mittal B, Bhattacharya A Indian J Nucl Med. 2021; 36(1):25-31.

PMID: 34040292 PMC: 8130693. DOI: 10.4103/ijnm.IJNM_158_20.

Neuroprotective Role of Selected Antioxidant Agents in Preventing Cisplatin-Induced Damage of Human Neurons In Vitro.

Popovic J, Klajn A, Paunesku T, Ma Q, Chen S, Lai B Cell Mol Neurobiol. 2019; 39(5):619-636.

PMID: 30874981 PMC: 6535150. DOI: 10.1007/s10571-019-00667-7.

The evaluation of protective and mitigating effects of vitamin C against side effects induced by radioiodine therapy.

Jafari E, Alavi M, Zal F Radiat Environ Biophys. 2018; 57(3):233-240.

PMID: 29860661 DOI: 10.1007/s00411-018-0744-7.

Amifostine does not protect thyroid cancer cells in DNA damaging models.

Klubo-Gwiezdzinska J, Costello Jr J, Jensen K, Patel A, Tkavc R, Van Nostrand D Endocr Connect. 2017; 6(7):469-478.

PMID: 28790138 PMC: 5597971. DOI: 10.1530/EC-17-0138.

References

Bohuslavizki K, Brenner W, Lassmann S, Tinnemeyer S, Tonshoff G, Sippel C . Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun. 1996; 17(8):681-6. DOI: 10.1097/00006231-199608000-00006. View

Utley J, QUINN C, WHITE F, Seaver N, Bloor C . Protection of normal tissue against late radiation injury by WR-2721. Radiat Res. 1981; 85(2):408-15. View

Rasey J, Krohn K, Grunbaum Z, Spence A, Menard T, Wade R . Synthesis, biodistribution, and autoradiography of radiolabeled S-2-(3-methylaminopropylamino)ethylphosphorothioic acid (WR-3689). Radiat Res. 1986; 106(3):366-79. View

Utley J, Phillips T, Kane L . Protection of normal tissues by WR2721 during fractionated irradiation. Int J Radiat Oncol Biol Phys. 1976; 1(7-8):699-703. DOI: 10.1016/0360-3016(76)90152-8. View

Bohuslavizki K, Brenner W, Lassmann S, Tinnemeyer S, Kalina S, Clausen M . [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy]. Nuklearmedizin. 1997; 36(3):103-9. View

Washburn L, CARLTON J, Hayes R . Distribution of WR-2721 in normal and malignant tissues of mice and rats bearing solid tumors: dependence on tumor type, drug dose and species. Radiat Res. 1974; 59(2):475-83. View

HELMAN J, Turner R, Fox P, Baum B . 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system. J Clin Invest. 1987; 79(5):1310-3. PMC: 424370. DOI: 10.1172/JCI112954. View

SODICOFF M, CONGER A, Trepper P, Pratt N . Short-term radioprotective effects of WR-2721 on the rat parotid glands. Radiat Res. 1978; 75(2):317-26. View

ALBRECHT H, Creutzig H . [Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author's transl)]. Rofo. 1976; 125(6):546-51. DOI: 10.1055/s-0029-1230516. View

10.

Rasey J, Grunbaum Z, Krohn K, Menard T, Spence A . Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913). Radiat Res. 1985; 102(1):130-7. View

11.

Rasey J, Spence A, Badger C, Krohn K, Vera D, Livesey J . Specific protection of different normal tissues. Pharmacol Ther. 1988; 39(1-3):33-43. DOI: 10.1016/0163-7258(88)90037-x. View

12.

Takahashi I, Nagai T, Miyaishi K, Maehara Y, NIIBE H . Clinical study of the radioprotective effects of Amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys. 1986; 12(6):935-8. DOI: 10.1016/0360-3016(86)90388-3. View

13.

SODICOFF M, CONGER A, Pratt N, Trepper P . Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. Radiat Res. 1978; 76(1):172-9. View

14.

Baum B . Principles of saliva secretion. Ann N Y Acad Sci. 1993; 694:17-23. DOI: 10.1111/j.1749-6632.1993.tb18338.x. View

15.

Phillips T, Kane L, Utley J . Radioprotection of tumor and normal tissues by thiophosphate compounds. Cancer. 1973; 32(3):528-35. DOI: 10.1002/1097-0142(197309)32:3<528::aid-cncr2820320303>3.0.co;2-c. View

16.

PATT H, TYREE E, STRAUBE R, Smith D . Cysteine Protection against X Irradiation. Science. 1949; 110(2852):213-4. DOI: 10.1126/science.110.2852.213. View

17.

Menard T, Izutsu K, Ensign W, Keller P, Morton T, Truelove E . Radioprotection by WR-2721 of gamma-irradiated rat parotid gland: effect on gland weight and secretion at 8-10 days post irradiation. Int J Radiat Oncol Biol Phys. 1984; 10(9):1555-9. DOI: 10.1016/0360-3016(84)90502-9. View

18.

Utley J, Marlowe C, Waddell W . Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2. Radiat Res. 1976; 68(2):284-91. View

19.

Rasey J, Krohn K, Menard T, Spence A . Comparative biodistribution and radioprotection studies with three radioprotective drugs in mouse tumors. Int J Radiat Oncol Biol Phys. 1986; 12(8):1487-90. DOI: 10.1016/0360-3016(86)90200-2. View

20.

Yuhas J, Spellman J, Culo F . The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials. 1980; 3(3):211-6. View